Aphios Pharma

Aphios is developing enabling technology platforms designed to improve drug discovery and manufacturing, nanotechnology drug delivery and pathogenic drug safety. Using these enabling technology platforms, Aphios and its collaborators are developing enhanced therapeutics for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and Central Nervous System (CNS) disorders

250 - Aphios Pharma stress ball

500 - Aphios Pharma cotton hat

1000 - Aphios Pharma first aid duffel

10000 - Aphios Pharma beach chair

Green biotech developing sustained release nanoencapsulated cannabinoids for highly unmet chronic medical needs
ESG opportunity addressing a $4B market for cancer pain, $5B for opioid use disorder and $40B for Multiple Sclerosis
Aphios has spent $44 million to date on developing enabling drug manufacturing and drug delivery technologies
Including $7.9M in peer-reviewed grants from National Cancer Institute, National Institute on Drug Abuse and NCCIH, NIH
Established supercritical fluid manufacturing facility for 1,000 kg pharma-grade cannabinoids per yr under cGMP
Fully-equipped Schedule I BSL-2 labs and cGMP suites for formulation and nanoencapsulation of cannabinoids
Our proprietary manufacturing and nanoencapsulation technologies are protected by 16 issued patents and 4 provisionals
We are dedicated to sustainability, environmental responsibility and communal curtailment of climate change

Green biotech developing sustained release nanoencapsulated cannabinoids for highly unmet chronic medical needs ESG opportunity addressing a $4B market for cancer pain, $5B for opioid use disorder and $40B for Multiple Sclerosis Aphios has spent $44 million to date on developing enabling drug manufacturing and drug delivery technologies Including $7.9M in peer-reviewed grants from National Cancer Institute, National Institute on Drug Abuse and NCCIH, NIH Established supercritical fluid manufacturing facility for 1,000 kg pharma-grade cannabinoids per yr under cGMP Fully-equipped Schedule I BSL-2 labs and cGMP suites for formulation and nanoencapsulation of cannabinoids Our proprietary manufacturing and nanoencapsulation technologies are protected by 16 issued patents and 4 provisionals We are dedicated to sustainability, environmental responsibility and communal curtailment of climate change